BioStock: Spermosens bidrag till att lösa ofrivillig barnlöshet

Se intervjun på biostock.se:

https://www.biostock.se/2024/04/spermosens-bidrag-till-att-losa-ofrivillig-barnloshet/

Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.biostock.se/

8 April, 2024

Press releases

Spermosens announces outcome of exercise of warrants series TO 5

17-06-2025 Regulatory

Spermosens AB (publ) (“Spermosens” or the “Company”) today announces the outcome of the exercise of warrants of series TO 5 (the “Warrants”). A total of 467,740,274 shares were subscribed for through the exercise of Warrants, corresponding to an exercise rate of 100 percent. Spermosens will receive proceeds of approximately SEK 2.6 million before transaction costs.

Spermosens AB Announces Results from Annual General Meeting on 16 June 2025

16-06-2025 Regulatory

Spermosens AB ("Spermosens" or the "Company") today held its Annual General Meeting in Lund. The following resolutions were adopted: The Annual Report and Auditor’s Report for the financial year 2024 were presented. CEO Tore Duvold provided a summary of the Company’s operations and key developments over the past year. The meeting resolved to adopt the […]

Chairman and CEO of Spermosens exercise TO5 warrants

13-06-2025 Regulatory

Spermosens AB (“Spermosens” or the “Company”) today announces that the Chairman of the Board, Ulrik Spork, and the CEO, Tore Duvold, have exercised their respective warrants of series TO5 for the subscription of new shares in the Company. Ulrik Spork has exercised 6,446,200 warrants, and Tore Duvold has exercised 5,750,000 warrants. The exercise of the […]

Spermosens concludes clinical study with statistically significant results supporting the diagnostic value of JUNO-Checked

11-06-2025 Regulatory

Spermosens AB (“Spermosens” or the “Company”) today announces positive topline results from its clinical study conducted at the Reproductive Medicine Center (RMC) in Malmö. The study was designed to validate the diagnostic value of the Company’s patented JUNO-Checked system and has now reached a successful conclusion. The results demonstrate a statistically significant correlation between the JUNO Score, a measurement of sperm binding to the JUNO receptor, and fertilization rate in IVF.

The capital raise and issue announced in March 2025 is approved by Inspectorate of Strategic Products

05-06-2025 Regulatory

On March 4, 2025 Spermosens announced that the company has secured a SEK 10.8 million strategic investment through a directed issue. The investment is fulfilling the capital need until mid-2026. At the same time, Spermosens assessed that the issue had to be notified according to the Act (2023:560) on the review of foreign direct investments. A notification was sent to the Inspectorate of Strategic Products. After review, the authority today informed Spermosens that it leaves the notification without further action, which basically is the same as approving the issue.